美国黑人女科学家对moderna疫苗开发做出重要贡献送交者: 黑5类[☆品衔R4☆] 于 2021-02-26 20:08 已读 2 次 大字阅读 
黑5类的个人频道
 
Kizzmekia Corbett 6park.com

From Wikipedia, the free encyclopedia 6park.com

Jump to navigationJump to search 6park.com
 6park.com
Kizzmekia Corbett
Born
Kizzmekia Shanta Corbett 6park.com

January 26, 1986 (age 35) 6park.com

Hurdle Mills, North Carolina, U.S.
Alma materUniversity of Maryland, Baltimore County (BS)
University of North Carolina, Chapel Hill (MS, PhD)Known forCOVID-19 vaccineScientific careerFieldsImmunology
MicrobiologyInstitutionsNational Institute of Allergy and Infectious DiseasesThesis"Characterization of Human Antibody Responses to Dengue Virus Infections in a Sri Lankan Pediatric Cohort" (2014)
Kizzmekia "Kizzy" Shanta Corbett (born January 26, 1986)[1] is an American viral immunologist at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID NIH) based in Bethesda, Maryland.[2][3] She earned a PhD in microbiology and immunology from the University of North Carolina at Chapel Hill (UNC-Chapel Hill) in 2014.[4] Appointed to the VRC in 2014, she is currently the scientific lead of the VRC's Coronavirus Team,[5] with research efforts aimed at propelling novel coronavirus vaccines, including a COVID-19 vaccine.[6][7] In December 2020, the Institute's Director, Dr. Anthony Fauci said: "Kizzy is an African American scientist who is right at the forefront of the development of the vaccine."[8] In February 2021, Corbett was highlighted in the Time's "Time100 Next" list[9] under the category of Innovators, with a profile written by Dr. Fauci.[10] In the Time's profile, Dr. Fauci wrote that Corbett has "been central to the development of the Moderna mRNA vaccine and the Eli Lilly therapeutic monoclonal antibody that were first to enter clinical trials in the U.S." and that "her work will have a substantial impact on ending the worst respiratory-disease pandemic in more than 100 years."[10] 6park.com

Contents

1Early life and education2Career2.1Development of COVID-19 vaccine3Academic service4Honors5Selected works and publications6References7External links
Early life and education[edit]
Corbett was born in Hurdle Mills, North Carolina to Rhonda Brooks.[3] She grew up in Hillsborough, North Carolina,[11] where she had a large family of step-siblings and foster siblings.[2]

Corbett went to Oak Lane Elementary School[12] and A.L. Stanback Middle School.[11][13] Her fourth grade teacher, Myrtis Bradsher, recalls recognizing Corbett's talent at an early age and encouraging Kizzy's mother to place her in advanced classes. "I always thought she is going to do something one day. She dotted i’s and crossed t’s. The best in my 30 years of teaching," Bradsher said in a 2020 interview with The Washington Post.[12]

In 2004, Corbett graduated from Orange High School in Hillsborough, North Carolina.[11] In 2008, Corbett received a B.S. in biological sciences and sociology from the University of Maryland, Baltimore County (UMBC), as a student in the Meyerhoff Scholars Program.[2] In 2014, Corbett received a PhD in microbiology and immunology from the University of North Carolina at Chapel Hill. For her doctoral work, Corbett worked in Sri Lanka to study the role of human antibodies in dengue virus pathogenesis.[4]

Career[edit]
While in high school, Corbett realized that she wanted to pursue a scientific career, and as part of a program called ProjectSEED, spent her summer holiday working in research laboratories, one of which was at UNC's Kenan Labs with organic chemist James Morkin.[1][2][11] In 2005, she was a summer intern at Stony Brook University in Gloria Viboud's lab where she studied Yersinia pseudotuberculosis pathogenesis. From 2006 to 2007, she worked as a lab tech in Susan Dorsey's lab at the University of Maryland School of Nursing.

After earning her bachelor's degree, from 2006 to 2009, Corbett was a biological sciences trainer at the National Institutes of Health (NIH), where she worked alongside Dr. Barney S. Graham. At the NIH, Corbett worked on the pathogenesis of respiratory syncytial virus as well as on a project focused on innovative vaccine platform advancement.[1]

From 2009 to 2014, Corbett studied human antibody responses to dengue virus in Sri Lankan children under the supervision of Aravinda de Silva at University of North Carolina at Chapel Hill (UNC-Chapel Hill).[4][14] She studied how people produce antibodies in response to dengue fever, and how the genetics of dengue fever impact the severity of a disease. From April to May 2014, as part of her research for her dissertation, Corbett worked as a visiting scholar at Genetech Research Institute in Colombo, Sri Lanka.[1]

In October 2014, Corbett became a research fellow working as a viral immunologist at the NIH. Her research aims to uncover mechanisms of viral pathogenesis and host immunity.[13] She specifically focuses on development of novel vaccines for coronaviridae.[13] Her early research considered the development of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) vaccine antigens.[15][16] During this time, she identified a simple way to make spike proteins that are stabilized in a conformation that renders them more immunogenic and manufacturable, in collaboration with researchers at Scripps Research Institute and Dartmouth College.[17]

Development of COVID-19 vaccine[edit]
At the onset of the COVID-19 pandemic, Corbett started working on a vaccine to protect people from coronavirus disease.[2] Recognizing that the virus was similar to severe acute respiratory syndrome coronavirus, Corbett's team utilized previous knowledge of optimal coronavirus S proteins to tackle the novel coronavirus.[18][19] S proteins form a “crown” on the surface of coronaviruses and are crucial for engagement of host cell receptors and the initiation of membrane fusion in coronavirus disease. This makes them a particularly vulnerable target for coronavirus prophylactics and therapeutics. Based on her previous research, Corbett's team, in collaboration with investigators at UT Austin, transplanted stabilizing mutations from SARS-CoV S protein into SARS-CoV-2 spike protein.[17] She was part of the NIH team who helped solve the cryogenic electron microscopy (CryoEM) structure of the SARS-CoV-2 spike protein.[20] Her prior research suggested that messenger RNA (mRNA) encoding S protein could be used to excite the immune response to produce protective antibodies against coronavirus disease 2019.[17][21]

To manufacture and test the COVID-19 vaccine Corbett's team partnered with Moderna, a biotechnology company, to rapidly enter animal studies. Subsequently, the vaccine entered Phase 1 clinical trial only 66 days after the virus sequence was released. The trial, to be completed in at least 45 people, is a dose escalation study in the form of two injections separated by 28 days.[22] Corbett's work afforded her the opportunity to be a part of the National Institutes of Health team that welcomed Donald Trump to the Dale and Betty Bumpers Vaccine Research Center in March 2020.[3][23][24][25]